Form 4: Director Deborah Keller Receives WST Restricted Stock Units
Statement of Changes in Beneficial Ownership
West Pharmaceutical Services director Deborah L. Keller was granted 791 restricted stock units as part of equity compensation.
Summary
- Director Deborah L. Keller acquired 791 restricted stock units (RSUs) of West Pharmaceutical Services, Inc. (WST).
- The transaction occurred on May 4, 2026, at a price of $0 per share, representing an equity grant.
- Following this transaction, the director's total beneficial ownership stands at 11,560.479 shares of common stock.
- The granted RSUs are scheduled to vest in full on the date of the next annual shareholder meeting.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified.
Risks
- Standard market risks associated with equity ownership and potential fluctuations in WST share price.
Future Outlook
The restricted stock units are set to vest in full upon the date of the next annual shareholder meeting.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice designed to incentivize long-term oversight and alignment with shareholder interests in the pharmaceutical packaging and delivery systems sector.
Comparison to Industry Standards
- The grant of restricted stock units to directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare companies.
- The vesting schedule tied to the annual shareholder meeting is a common practice for director equity awards.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity compensation grant.
Next Steps
- Vesting of the 791 restricted stock units at the next annual shareholder meeting.
Key Dates
| Date | Description |
|---|---|
| 05/04/2026 | Date of the RSU grant transaction. |
| 05/06/2026 | Date of filing the Form 4. |
Keywords
WST, West Pharmaceutical Services, Form 4, Insider Trading, Director Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.